anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
STUDY OBJECTIVES: The association of in-hospital medical emergency team activation (META) among patients with atrial fibrillation (AF) at risk for obstructive sleep apnea (OSA) is unclear. This study evaluates the performance of the DOISNORE50 sleep questionnaire as an OSA screener for patients with AF and determines the prevalence of META among perioperative patients with underlying AF who have a diagnosis or are at risk for OSA.
METHODS: A prospective perioperative cohort of 2,926 patients with the diagnosis of AF was assessed for DOISNORE50 questionnaire screening. Propensity-score matching was used to match patients' physical characteristics, comorbidities, length of stay, and inpatient continuous positive airway pressure device usage. META and intensive care unit admissions during the surgical encounter, 30-day hospital readmissions, and 30-day emergency department visits were evaluated.
RESULTS: A total of 1,509 out of 2,926 AF patients completed the DOISNORE50 questionnaire and were enrolled in the OSA safety protocol. Following propensity-score matching, there were reduced adjusted odds of META in the screened group of 0.69 (95% confidence interval: 0.48-0.98, P < .001) in comparison to the unscreened group. The adjusted odds of intensive care unit admissions and emergency department visits within 30 days of discharge were statistically lower for the screened group compared with the unscreened group.
CONCLUSIONS: Among perioperative AF patients, evidence supports DOISNORE50 screening and implementation of an OSA safety protocol for reduction of META. This study identified decreased odds of META, intensive care unit admissions, and emergency department visits among the screened group. The high-risk and known OSA group showed reduced odds of META following the implementation of an OSA safety protocol.
CITATION: Saha AK, Sheehan KN, Xiang KR, et al. Preoperative sleep apnea screening protocol reduces medical emergency team activation in patients with atrial fibrillation. J Clin Sleep Med. 2024;20(5):783-792.
PURPOSE:To obtain the titled emulsion having prolonged half-life in living bodies and improved effectiveness and safety of a drug transmitted to the target site of the drug with high selectivity, by embedding the drug in emulsion particles of fluorinated hydrocarbons. CONSTITUTION:An emulsion obtained by embedding a drug in an emulsion consisting of (A) 1-50% (wt./vol.) fluorinated hydrocarbons which are 9-12C liquid saturated perfluorocarbons forming at least one saturated aliphatic ring, heterocyclic ring having one or more N and/or O as hetero-atoms. aliphatic tertiary amine or aliphatic ether, (B) 0.2-10% (wt./vol.) emulsifying agent, such as high polymer based nonionic surfactant or phospholipid, and (C) an adequate amount of water. The aimed drug-containing emulsion can be obtained simply by blending the respective ingredients. Furthermore, a drug-containing emulsion of the type prepared in use for an unstable drug which is hard to preserve in an emulsion for a long period can be obtained by blending the drug in a previously prepared emulsion.
Induction therapy: Patients receive carboplatin IV (175/m2) over 1 hour on days 1, 8, 15, and 22; vincristine IV (1.5 mg/m2) on days 1, 8, 15, 22, 29, and 36; and oral temozolomide (200 mg/m2) on days 43-47. Four weeks after the completion of induction therapy, patients achieving stable or responding disease proceed to maintenance therapy. Maintenance therapy: Patients receive carboplatin (175/m2) and temozolomide (200 mg/m2) as in induction therapy and vincristine IV ((1.5 mg/m2) day 1 of weeks 10,11,12. Treatment repeats every 10 weeks for a total of 6 courses in the absence of disease progression.
One of the most common medical conditions seen in general hospital is somatic symptoms disorder (SSD). As the disorder is characterized by the prominent attention to somatic concerns, patients mainly present initially in medical rather than mental health care settings. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) is currently the "gold standard" for the diagnosis of SSD, but it is clinically hard to follow. Thus, It is more clinically practical to detect a disorder by self-administered questionnaires, that patients can score symptoms according to their own condition and severity in a short time. However, the current self-reporting questionnaires, such as the Patient Health Questionnaire-9 (PHQ-9), the Generalized Anxiety Disorder Scale-7 (GAD-7), and the Patient Health Questionnaire-15 (PHQ-15) are neither sufficiently considering companioned anxiety or depression nor validated for monitor the treatment efficacy of SSD patients.

The Somatic Symptom Scale-China (SSS-CN) is developed based on DSM-5 to assess SSD, and it is an abbreviated 20-item version of somatic symptoms that can be entirely self-administered by the patient, but its assessment value has not yet been widely tested. The study aims to investigate whether the SSS-CN could serve as a timely and practical instrument to detect SSD and assess the severity of the disorder.
Children aged 3 \< 4 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
BACKGROUND: Nosocomial infections (NIs) frequently occur and adversely impact prognosis for hospitalized patients with cirrhosis. This study aims to develop and validate two machine learning models for NIs and in-hospital mortality risk prediction.
METHODS: The Prediction of Nosocomial Infection and Prognosis in Cirrhotic patients (PIPC) study included hospitalized patients with cirrhosis at the Qingchun Campus of the First Affiliated Hospital of Zhejiang University. We then assessed several machine learning algorithms to construct predictive models for NIs and prognosis. We validated the best-performing models with bootstrapping techniques and an external validation dataset. The accuracy of the predictions was evaluated through sensitivity, specificity, predictive values, and likelihood ratios, while predictive robustness was examined through subgroup analyses and comparisons between models.
RESULTS: We enrolled 1,297 patients into derivation cohort and 496 patients into external validation cohort. Among the six algorithms assessed, the Random Forest algorithm performed best. For NIs, the PIPC-NI model achieved an area under the curve (AUC) of 0.784 (95% confidence interval [CI] 0.741-0.826), a sensitivity of 0.712, and a specificity of 0.702. For in-hospital mortality, the PIPC- mortality model achieved an AUC of 0.793 (95% CI 0.749-0.836), a sensitivity of 0.769, and a specificity of 0.701. Moreover, our PIPC models demonstrated superior predictive performance compared to the existing MELD, MELD-Na, and Child-Pugh scores.
CONCLUSIONS: The PIPC models showed good predictive power and may facilitate healthcare providers in easily assessing the risk of NIs and prognosis among hospitalized patients with cirrhosis.
Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) is a serious chronic sleep disorder. Snoring is a common and easily observable symptom of OSAHS patients. The purpose of this work is to identify OSAHS patients by analyzing the acoustic characteristics of snoring sounds throughout the entire night. Ten types of acoustic features, such as Mel-frequency cepstral coefficients (MFCC), linear prediction coefficients (LPC) and spectral entropy among others, were extracted from the snoring sounds. A fused feature selection algorithm based on ReliefF and Max-Relevance and Min-Redundancy (mRMR) was proposed for optimal feature set selection. Four types of machine learning models were then applied to validate the effectiveness of OSAHS patient identification. The results show that the proposed feature selection algorithm can effectively select features with high contribution, including MFCC and LPC. Based on the selected top-20 features and using a support vector machine model, the accuracies in identifying OSAHS patients under the thresholds of AHI = 5,15, and 30, were 100%, 100%, and 98.94%, respectively. This indicates that the proposed model can effectively identify OSAHS patients.
For the relief of signs and symptoms of rheumatoid arthritis or osteoarthritis the recommended dose is 400 mg to 600 mg given orally, 3 or 4 times a day. The dose should be tailored to the needs of the patient and may be increased or decreased depending on the severity of the symptoms. Dosage adjustments may be made after initiation of drug therapy or during exacerbations of the disease. Total daily dosage should not exceed 3200 mg.

NALFON tablets may be administered with meals or with milk. Although the total amount absorbed is not affected, peak blood levels are delayed and diminished.

Patients with rheumatoid arthritis generally seem to require larger doses of NALFON tablets than do those with osteoarthritis. The smallest dose that yields acceptable control should be employed.

Although improvement may be seen in a few days in many patients, an additional 2 to 3 weeks may be required to gauge the full benefits of therapy.
PURPOSE:To prepare a formulation used for embedding in a bone and capable of reinforcing the repair of the osseous tissue, while gradually releasing a medicine. CONSTITUTION:This formulation for embedding in a bone is obtained by mixing molded products with artificial bone components and subsequently coating the molded product with the artificial bone components. The molded products are obtained by compression-molding a medicine and a polymeric substance or melting the medicine and the polymeric substance and subsequently solidifying the melted product. The medicine includes various antibiotics and antitumor agents, and any component among conventional components can be used as the artificial bone components. A biologically degradable substance is desirably used as the polymeric substance. The release of the medicine from the formulation for embedding in the bone can easily be controlled Once after embedded in the bone, the discharge of the formulation is not necessary.
PROBLEM TO BE SOLVED: To obtain a new bicyclic type (meth)acrylate converted into a functional group, suitable as a dental material or a constituent component thereof and especially useful as a raw material for promoting the adhesion of a dentine adhesive. SOLUTION: This new bicyclic type (meth)acrylate converted into a functional group is represented by formula I or II [A-B is C-C or C=C, X is CH2 , O, etc.; Z is CH2 =CH-CO, etc.; V is an alkleneoxy, CH2 -S, etc.; Y is H, an alkyl, an aryl, etc.; T is an alkyl, an aryl, a halogen, NO2 etc.; Y and T together form CO-O-CO, etc.; U is an alkyleneoxy, etc.; W is an (m)-fold substituted alkylene], e.g. exo-1-[(methacryloyloxy)methyl]-7-oxabicyclo[2.2.1]hept-5-ene-2,3- dicarboxylic anhydride. The compound represented by formula I is obtained by reacting a compound represented by formula III with a compound represented by formula IV. The compound represented by formula II is prepared by reacting a compound represented by formula V with a compound represented by the formula (OH)m W.
The invention discloses a medicine for treating rectal cancer and a preparation method and application thereof. The medicine is prepared from, by weight, 11-19 parts of tea polyphenols, 1-5 parts of citric acid, 15-23 parts of isorhamnetin and 5-12 parts of Herba Hedyotis. The preparation method comprises the steps of mixing the tea polyphenols and the isorhammetin, adding deionized water weighing 3.7 times of the total mass of the polyphenols and the isorhammetin, conducting ultrasonic treatment at the temperature of 42 DEG C for 18 minutes to acquire a mixture A, mixing herba hedyotis with the mixture A, conducting microwave treatment for 3 minutes to acquire a mixture B, mixing citric acid with the mixture B, conducting ultrasonic treatment at a temperature of 58 DEG C for 20 minutes, and stirring at the temperature of 60 DEG C till the product is dried to acquire the medicine. The medicine for treating rectal cancer takes the advantages of the synergistic functions of all the materials for the treatment of rectal cancer with remarkable curing effects, and is particularly suitable for the treatment of early symptoms of rectal cancer. The medicine for treating rectal cancer can be used singularly for the treatment, and can also be used with the combination of surgical operation, radiotherapy or chemotherapy to treat both the symptoms and root causes. The medicine for treating rectal cancer has no toxic effects and side effects. The patients can use the medicine for treating rectal cancer securely and conveniently.
Methods, computer systems, and computer readable media for transitioning a clinical care room from a first scene to a second scene in order to facilitate completion of a real-world activity are provided. The first scene in the clinical care room is presented where the clinical care room has one or more zones. The first scene is associated with a first group of setting for components within the one or more zones. An input corresponding to the real-world activity is received. Incident to receiving the input, the second scene is provided. The second scene is associated with a second group of settings for the components. The second group of setting is optimized to facilitate completion of the real-world activity.
Cellular senescence contributes to inflammatory kidney disease via the secretion of inflammatory and profibrotic factors. Protease-activating receptor 2 (PAR2) is a key regulator of inflammation in kidney diseases. However, the relationship between PAR2 and cellular senescence in kidney disease has not yet been described. In this study, we found that PAR2-mediated metabolic changes in renal tubular epithelial cells induced cellular senescence and increased inflammatory responses. Using an aging and renal injury model, PAR2 expression was shown to be associated with cellular senescence. Under in vitro conditions in NRK52E cells, PAR2 activation induces tubular epithelial cell senescence and senescent cells showed defective fatty acid oxidation (FAO). Cpt1α inhibition showed similar senescent phenotype in the cells, implicating the important role of defective FAO in senescence. Finally, we subjected mice lacking PAR2 to aging and renal injury. PAR2-deficient kidneys are protected from adenine- and cisplatin-induced renal fibrosis and injury, respectively, by reducing senescence and inflammation. Moreover, kidneys lacking PAR2 exhibited reduced numbers of senescent cells and inflammation during aging. These findings offer fresh insights into the mechanisms underlying renal senescence and indicate that targeting PAR2 or FAO may be a promising therapeutic approach for managing kidney injury.
Liver Cancer

In the Swedish Breast Cancer Cooperative Group trial using adjuvant tamoxifen 40 mg per day (two times the recommended dosage) for 2 to 5 years, 3 cases of liver cancer were reported in the tamoxifen-treated group versus 1 case in the observation group [see Clinical Studies (14.2)]. One case of liver cancer was reported in NSABP P-1 (women at high risk for breast cancer) in a participant randomized to tamoxifen [see Clinical Studies (14.4)].

Hepatocellular carcinoma has been observed in animals receiving tamoxifen [see Nonclinical Toxicology (13.1)].

Non-Malignant Effects on the Liver

Tamoxifen has been associated with changes in liver enzyme levels, and on rare occasions, a spectrum of more severe liver abnormalities including fatty liver, cholestasis, hepatitis and hepatic necrosis. Some of these serious cases included fatalities. In most reported cases, the relationship to tamoxifen is uncertain. However, some positive rechallenges and dechallenges have been reported. Monitor liver function periodically.

In the NSABP P-1 trial, grade 3 to 4 changes in liver function (SGOT, SGPT, bilirubin, alkaline phosphatase) were observed (10 on placebo and 6 on tamoxifen). Serum lipids were not systematically collected.
PURPOSE:To obtain the titled plastic prevented from undergoing mutual adhesion of particles during storage and having a persistent medicinal effect, by mixing medicated plastic particles with non-medicated plastic powders of a softening point higher than that of the medicated particles and heating the mixture with a high-frequency current. CONSTITUTION:Medicated plastic particles are mixed with non-medicated plastic powders having m.p. or a softening point higher than that of the medicated particles. This mixture is heated with a high-frequency current to soften the medicated plastic particles to adhere unsoftened non-medicated plastic powder to the surfaces of the medicated particles. The medicated plastic particles to be used are usually those of a thermoplastic synthetic resin, and one compatible with chemicals is desirable. Examples of the chemicals include perfumes, rust- preventive, agents, fungicides, insect repellents, rodent repellents, deodorants, insecticides and stain-proof agents.
PURPOSE:To prepare the titled drug having carcinostatic activity, by drying polypores, crushing to a proper small pieces to obtain cotton-like or fibrous material, and mixing calcium thereto. CONSTITUTION:Fungus belonging to Polyporaceae family (e.g. Ganoderma lucidum, Elfvingia applanata, Phellinus yucatensis, Fomitopsis pinicola, Grifola umbellata, Phellinus igniarius, Lenzites betulina, Fomes fomentarius, etc.) is dried at normal temperature, cut with a cutter to the width of several millimeters, and crushed. The fungus is not pulverized owing to its texture, but becomes cotton-like or fibrous. A calcium compound (e.g. calcium phosphate, calcium lactate, calcium citrate, etc.) is added to the crushed fungus, and mixed uniformly. The amount of the calcium is preferably about 10% based on the raw material such as Ganoderma lucidum. If necessary, the mixture is further mixed with a vehicle and an additive such as lactose disintegrant, etc., and formed to obtain the polypore drug. EFFECT:It can be prepared without troublesome processes, and can be administered extremely easily. Furthermore, the synergistic effect of calcium can be expected.
A terminal communicates with a serving base station and at least one soft handoff (SHO) base station for soft handoff on the reverse link in a wireless communication system. In one design, the serving base station schedules the terminal for transmission on the reverse link, forms an assignment for the terminal, and generates signaling for the terminal. The assignment indicates communication parameter(s) to be used by the terminal for transmission on the reverse link. The signaling contains sufficient information to allow the SHO base station(s) to receive and process the transmission from the terminal. The serving base station sends the signaling via a backhaul to the SHO base station(s). Each SHO base station receives the signaling via the backhaul, receives the transmission from the terminal via the reverse link, and processes the transmission in accordance with the signaling to recover the data sent in the transmission.
Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of radiation therapy (RT).
BACKGROUND: Surgical removal of deep infiltrating endometriosis is frequently associated with improvement in symptoms. However, because of the complex pathogenesis of pain in endometriosis that includes central sensitization and myofascial dysfunction, symptoms can persist after surgery. The aim of the present observational study is to explore the effectiveness of osteopathic manipulative treatment (OMT) in reducing persistent pelvic pain and dyspareunia in a sample of symptomatic women surgically treated for endometriosis.
METHODS: Retrospective cohort analysis of 69 patients treated with OMT, for persistent myofascial pain, chronic pelvic pain (CPP) and dyspareunia after surgical eradication of endometriosis. Surgical, clinical and osteopathic reports were retrospectively analyzed in a chart review. Osteopathic interventions included myofascial release, balanced ligamentous/membranous tension and indirect fluidic technique.
RESULTS: During the study period 345 patients underwent surgery for symptomatic endometriosis. Among them, 97 patients (28.1%) complained of post-operative persistent CPP and dyspareunia and 69 patients underwent osteopathic treatment. OMT reports showed a significant improvement of the symptoms after the first OMT session. Particularly, lower scores of CPP (mean NRS 4±4.2 vs. 0.2±0.7, P value.
CONCLUSIONS: OMT, breaking the cycle of pain and normalizing the musculoskeletal pelvic activity, could be a successful technique to treat persistent chronic pain in women surgically treated for endometriosis.
The intervention will be educational in the form of the provision of contemporary pain science education and supportive advice from people with a history of persistent pain. The duration of the webinar will be 90 minutes.
Disclosed is a method of treating diseases. traumas. as well as consequences of traumas of the central nervous system. and a method for stimulating neurons regeneration. which involves the use of a peptide glutamyl-aspartyl-arginine. Also disclosed are a pharmaceutical composition containing the above peptide and a pharmaceutically acceptable carrier and a method of stimulating the regeneration of neurons by administering to a patient a pharmaceutical composition containing the above peptide in the dose of 0.01-100 μg/kg of body weight at least once a day during a period necessary for attaining the therapeutic effect. such administration being performed parenterally.
This invention relates to a system for recording, analyzing risk(s) of accident(s) or need of assistance and providing real-time warning(s) based on continuous sensor signals, wherein the system according to this invention comprising at least one measuring device(s) and at least one administrative device(s), wherein the said measuring device(s) receives various data related to the user for processing and displaying on the administrative device(s). More complex system may comprise of at least one signal fusion device(s) for transferring data related to the examinee(s), for a wider area of coverage, and/or at least one server(s) that records various data related to the examinee and administrator(s), in order to playback, process and/or transfer data to other administrative device(s) or transfer warning data to relative(s) of the examinee. The data analytical-processing step may be performed on the measuring device(s) itself or distributed to various parts of the system. Wherein said data processing step comprises a data processing and displaying step, which further comprising a data input step, a context recognition step, an inference for estimating risk and a warning step, a database record step, a display step, and a warning configuration step. The system for recording, analyzing risk(s) of accident(s) or need of assistance and providing real-time warning(s) based on continuous sensor signals according to this invention can continuously notify various data measurement and analysis related to the examinee and warn the administrator(s) when the examinee is at risk as identified in the system for a particular examinee. This allows the administrator(s) to help or adjust the state of the examinee appropriately, in order to reduce a chance of unwanted incidents that may happen to the examinee. Moreover, the measured data can also be used by physician(s) or the administrator(s) to analyze for diagnosis, treatment and caring methods for the examinee.